公开(公告)号：US20220056133A1

公开(公告)日：2022-02-24

申请号：US17417570

申请日：2019-12-24

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Dmitry Borisovich STAROVEROV ,  Anna Valentinovna EVSTRATEVA ,  Alexey Konstantinovich MISORIN ,  Timofey Aleksandrovich NEMANKIN ,  Mariia Aleksandrovna SHCHEMELEVA ,  Anna Konstantinovna VLADIMIROVA ,  Arina Vitalevna ANIKINA ,  Roman Alekseevich IVANOV ,  Dmitry Valentinovich MOROZOV ,  Pavel Andreevich IAKOVLEV ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

公开(公告)号：US20230357396A1

公开(公告)日：2023-11-09

申请号：US18103194

申请日：2023-01-30

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Mark Aleksandrovic IZRAELSON ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2809 ,  A61K39/3955 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.

公开(公告)号：US20220112286A1

公开(公告)日：2022-04-14

申请号：US17417686

申请日：2020-02-20

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Dmitry Borisovich STAROVEROV ,  Anna Valentinovna EVSTRATEVA ,  Alexey Konstantinovich MISORIN ,  Timofey Aleksandrovich NEMANKIN ,  Mariia Aleksandrovna SHCHEMELEVA ,  Anna Konstantinovna VLADIMIROVA ,  Arina Vitalevna ANIKINA ,  Roman Alekseevich IVANOV ,  Dmitry Valentinovich MOROZOV ,  Pavel Andreevich IAKOVLEV ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28

Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

公开(公告)号：US20200332003A1

公开(公告)日：2020-10-22

申请号：US16957328

申请日：2018-12-25

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Mark Aleksandrovic IZRAELSON ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28 ,  A61K39/395

Abstract: The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.